Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -74.69
- Piotroski Score 2.00
- Grade N/A
- Symbol (SILO)
- Company Silo Pharma, Inc.
- Price $0.99
- Changes Percentage (-10.09%)
- Change -$0.11
- Day Low $0.98
- Day High $1.10
- Year High $4.50
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.17
- Trailing P/E Ratio -2.1
- Forward P/E Ratio -2.1
- P/E Growth -2.1
- Net Income $-3,700,683
Income Statement
Quarterly
Annual
Latest News of SILO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Who Is David Oyelowo's Wife? All About Producer Jessica Oyelowo and Her Relationship With the 'Silo' Actor
Emily Krauser is a contributing writer at PEOPLE since 2022. She has also written for Entertainment Tonight, Style Network, Parade, and J-14 Magazine....
By PEOPLE.com | 2 days ago -
Epsilon Energy expands footprint in Alberta, Canada, with two new JVs
Epsilon Energy, a US company, has formed JVs in Alberta, Canada's Garrington and Harmattan areas with a Calgary-based private operator....
By Yahoo! Finance | 3 weeks ago -
JD Vance's burns of the media 'elite' reveal how siloed they are from...
According to Gallup, the media is America's least-trusted institution. JD Vance has been challenging mainstream media, exposing their disconnect from ordinary Americans. Vance's confrontations with jo...
By New York Post | 1 month ago
